查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1593894

肺癌药物市场：依疾病、分子、通路划分 - 全球预测 2025-2030

Lung Cancer Drugs Market by Disease (Non-Small Cell Lung Cancer, Small Cell Lung cancer), Molecule (Biologics, Small Molecules), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年肺癌治疗市值为247.6亿美元，预计到2024年将达到269.8亿美元，复合年增长率为9.06%，到2030年将达到454.5亿美元。

肺癌药物的范围包括旨在治疗不同类型肺癌的广泛治疗和介入措施，包括非小细胞肺癌（NSCLC）和小细胞肺癌（SCLC）。这些治疗范围从传统的化疗和放射线治疗到尖端的免疫疗法和分子标靶治疗。全球与肺癌相关的高盛行率和死亡率凸显了对肺癌治疗的需求。其应用范围从初级治疗到安宁疗护，最终用途主要是医院、癌症研究机构和提供癌症治疗的专业中心。该市场的关键成长要素包括由于吸烟和空气污染导致的肺癌发病率增加、个人化医疗的进步以及生物相似药的采用增加。最新的商机来自次世代定序和 CRISPR 技术的持续发展，为根据个人基因图谱量身定制的精准医疗铺平了道路，有可能改善治疗结果。此外，新兴市场医疗保健基础设施的成长正在创造新的扩张机会。然而，挑战依然存在，包括高昂的药品成本、严格的法律规范以及漫长的临床试验带来的巨大财务负担，这些可能会阻碍市场进入。创新可以集中于识别生物标记、研究抗药性机制以及提高现有药物有效性的联合治疗。探索联盟和收购以加强研发能力也可能有益。市场的本质是动态和竞争的，受到不断的科学发现以及生物相似药和学名药的进入造成价格竞争的推动。该领域的成功需要对研发进行策略性投资、对监管环境的深入了解以及开拓服务于多元化全球市场的强大分销网络。

主要市场统计
基准年[2023] 247.6亿美元
预测年份 [2024] 269.8亿美元
预测年份 [2030] 454.5亿美元
复合年增长率（%） 9.06%

市场动态：揭示快速发展的肺癌药物市场的关键市场洞察

供需的动态交互作用正在改变肺癌药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 肺癌患者增加
    • 消费者对标靶治疗治疗的需求不断增长
    • 全球吸烟者人数不断增加
    • 政府对肺癌控制的有利支持
  • 市场限制因素
    • 肺癌药物的副作用
  • 市场机会
    • 正在进行的肺癌治疗研究活动
    • 新药领域技术进步
  • 市场挑战
    • 生物製药和标靶治疗的可用性以及肺癌治疗成本的上升

波特五力：驾驭肺癌药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对肺癌药物市场的影响

外部宏观环境因素对肺癌治疗药物市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解肺癌治疗药物市场的竞争状况

肺癌治疗药物市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 肺癌药物市场定位矩阵供应商绩效评估

FPNV定位矩阵是评估肺癌治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划肺癌药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对肺癌药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 肺癌病例数和发生率不断增加
      • 消费者对标靶治疗的需求不断增长
      • 全球吸烟者人数不断增加
      • 政府对肺癌控制的有利支持
    • 抑制因素
      • 肺癌药物的副作用
    • 机会
      • 正在进行的肺癌治疗研究活动
      • 新药领域技术进步
    • 任务
      • 生物製药和标靶治疗的可用性以及肺癌治疗的高成本
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章肺癌治疗药物市场：依疾病分类

  • 非小细胞肺癌
  • 小细胞肺癌

第七章 按分子分類的肺癌药物市场

  • 生物製药
  • 小分子

第八章肺癌治疗药物市场：依分销管道分类

  • 离线
  • 在线的

第九章北美和南美肺癌药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太肺癌药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲肺癌药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly & Company Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.
Product Code: MRR-434CCDA05288

The Lung Cancer Drugs Market was valued at USD 24.76 billion in 2023, expected to reach USD 26.98 billion in 2024, and is projected to grow at a CAGR of 9.06%, to USD 45.45 billion by 2030.

The scope of lung cancer drugs encompasses a broad array of therapeutics and interventions aimed at treating various types of lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). These treatments range from traditional chemotherapy and radiation therapies to cutting-edge immunotherapies and targeted treatments. The necessity of lung cancer drugs is underscored by the high prevalence and mortality rates associated with lung cancer globally. Their application spans from initial treatments to palliative care, and end-use primarily involves hospitals, cancer research institutes, and specialty centers providing oncology care. Key growth influences in this market include increasing incidences of lung cancer due to smoking and air pollution, advancements in personalized medicine, and the rising adoption of biosimilars. The latest opportunities arise with the ongoing development of next-generation sequencing and CRISPR technology, which open avenues for precision medicine tailored to individual genetic profiles, potentially improving treatment outcomes. Additionally, the growth of healthcare infrastructure in emerging markets presents new opportunities for expansion. However, challenges persist, such as high drug costs, stringent regulatory frameworks, and the significant financial burden associated with lengthy clinical trials, which may hinder market access. Innovation can focus on research into biomarker identification, drug resistance mechanisms, and combination therapies that enhance the efficacy of existing drugs. Exploring partnerships or acquisitions to bolster R&D capabilities may also prove beneficial. The market's nature is dynamic and competitive, driven by continuous scientific discoveries and the entry of biosimilars and generics that create price competition. Success in this arena demands strategic investments in R&D and a keen understanding of regulatory landscapes, along with developing robust distribution networks to reach diverse global markets.

KEY MARKET STATISTICS
Base Year [2023] USD 24.76 billion
Estimated Year [2024] USD 26.98 billion
Forecast Year [2030] USD 45.45 billion
CAGR (%) 9.06%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lung Cancer Drugs Market

The Lung Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising cases and incidences of lung cancer
    • Growing demand for the targeted therapies by consumers
    • Increase in the number of smokers across the globe
    • Favorable government support to control lung cancer
  • Market Restraints
    • Side effects of lung cancer drugs
  • Market Opportunities
    • Ongoing research activities in the lung cancer treatments
    • Technological advancement in the fields of novel drugs
  • Market Challenges
    • Availability of biologics & targeted therapies and high cost of lung cancer treatments

Porter's Five Forces: A Strategic Tool for Navigating the Lung Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lung Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lung Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lung Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lung Cancer Drugs Market

A detailed market share analysis in the Lung Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lung Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lung Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lung Cancer Drugs Market

A strategic analysis of the Lung Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lung Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca PLC, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly & Company Ltd., F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Incyte Corporation, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi S.A., and Takeda Pharmaceutical Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Lung Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease, market is studied across Non-Small Cell Lung Cancer and Small Cell Lung cancer.
  • Based on Molecule, market is studied across Biologics and Small Molecules.
  • Based on Distribution Channel, market is studied across Offline and Online.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising cases and incidences of lung cancer
      • 5.1.1.2. Growing demand for the targeted therapies by consumers
      • 5.1.1.3. Increase in the number of smokers across the globe
      • 5.1.1.4. Favorable government support to control lung cancer
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects of lung cancer drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research activities in the lung cancer treatments
      • 5.1.3.2. Technological advancement in the fields of novel drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of biologics & targeted therapies and high cost of lung cancer treatments
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Lung Cancer Drugs Market, by Disease

  • 6.1. Introduction
  • 6.2. Non-Small Cell Lung Cancer
  • 6.3. Small Cell Lung cancer

7. Lung Cancer Drugs Market, by Molecule

  • 7.1. Introduction
  • 7.2. Biologics
  • 7.3. Small Molecules

8. Lung Cancer Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Offline
  • 8.3. Online

9. Americas Lung Cancer Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Lung Cancer Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Lung Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. AstraZeneca PLC
  • 3. Boehringer Ingelheim GmbH
  • 4. Bristol-Myers Squibb Company
  • 5. Eli Lilly & Company Ltd.
  • 6. F. Hoffmann-La Roche AG
  • 7. GlaxoSmithKline PLC
  • 8. Incyte Corporation
  • 9. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • 10. Johnson & Johnson Services, Inc.
  • 11. Merck & Co., Inc.
  • 12. Novartis AG
  • 13. Pfizer, Inc.
  • 14. Sanofi S.A.
  • 15. Takeda Pharmaceutical Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. LUNG CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. LUNG CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LUNG CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. LUNG CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. LUNG CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LUNG CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LUNG CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LUNG CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. LUNG CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 144. LUNG CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023